Joint Preservation Therapy Solutions in Bellevue, WA

CDC PLACES vs. JF: two files, not one brochure

Bellevue is a city under 250k (151,854 Census). CDC PLACES (2023, crude) estimates 6.9% of adults in Bellevue have diagnosed diabetes — 5.1 points below the U.S. 12% figure. Adult arthritis here is 17.8% (CDC PLACES 2023, crude). That is the joint-pain backdrop for PRP and orthobiologics — not a promise that every arthritic knee is a candidate. Keep 361 tissue, autologous PRP, and skin substitutes on different tickets. We onboard against that split — then ship.

Epidemiology is not a protocol

• Adult arthritis here is 17.8% (CDC PLACES 2023, crude). That is the joint-pain backdrop for PRP and orthobiologics — not a promise that every arthritic knee is a candidate. 5.4% of adults 18–64 here currently lack health insurance (CDC PLACES ACCESS2, 2023). Cash-pay PRP and Medicare CTPs cannot share one consent script. PRP is autologous and not a 361 allograft, but “patient prefers regenerative” is still not medical necessity in Washington.
• Orthopedic and wound-care buyers in Washington are often different people inside the same health system. A single Hawk Medical account can still require two utilization policies so 361 tissue and CTPs are not interchanged.
• In a city under 250k, vendor noise is the operational problem: too many look-alike allograft flyers, too little chain-of-custody paperwork. Hawk Medical ships nationwide with HCT/P documentation; we do not invent a Bellevue street address.

Uninsured mix and Medicare CTPs in the same building

JF reviewers still want serial wound measurements and conservative-care history before CTPs, whether diabetes in Bellevue is 6.9% or not. PLACES is planning data. The LCD is the claim.

Before the first joint preservation therapy shipment